查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1534251

全球泌尿生殖药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Genitourinary Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 130 Pages | 商品交期: 最快1-2个工作天内

价格

全球泌尿生殖药物市场需求预计将从 2023 年的 352.3 亿美元达到近 412.2 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 1.76%。

泌尿生殖药物是一种旨在治疗影响泌尿道和生殖器官的失调和疾病的药剂。这些药物涵盖各种治疗类别，包括抗生素、抗病毒药物、抗真菌药物、荷尔蒙和免疫抑制剂。它们用于治疗泌尿道感染（UTI）、勃起功能障碍、良性前列腺增生（BPH）、不孕症、性传染感染（STI）和各种泌尿生殖系统癌症等疾病。根据所治疗的疾病或病症，这些药物可能针对病原体、调节荷尔蒙水平、减少发炎或抑制癌细胞生长。

市场动态

泌尿生殖药物市场是由泌尿生殖疾病盛行率不断上升、药物开发的进步以及不断变化的医疗保健人口统计所推动的。泌尿道感染、摄护腺疾病和性传染病等泌尿生殖系统疾病的发生率不断上升，推动了对有效药物治疗的需求。快速的都市化、生活方式的改变和人口老化导致疾病负担增加，需要泌尿生殖药物疗法的持续创新。此外，药物输送系统、个人化医疗方法和生物标记识别的进步提高了治疗效果和患者结果。针对前列腺癌和勃起功能障碍等疾病的标靶治疗正在扩大治疗选择并改善受影响个体的生活品质。此外，不断增长的医疗保健支出和泌尿外科研究投资推动了市场扩张。製药公司专注于开发新疗法并扩大现有药物的适应症，以满足泌尿生殖医学中未满足的医疗需求。提高生殖健康意识、主动筛检措施和病患教育计画也促进泌尿生殖药物市场的成长。医疗保健提供者和政策制定者优先考虑预防保健和早期干预策略，以支持泌尿生殖药物的市场吸收。然而，药品审批和专利到期的严格监管要求对市场成长提出了挑战。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球泌尿生殖药物市场的各个细分市场进行了包容性评估。泌尿生殖药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

泌尿生殖药物市场报告的这一部分提供了有关国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按指示

  • 摄护腺癌
  • 卵巢癌
  • 膀胱癌
  • 子宫颈癌
  • 肾癌
  • 性功能障碍
  • 泌尿道感染
  • 尿失禁和膀胱过动症
  • 性传染病
  • 间质性膀胱炎
  • 血尿
  • 良性摄护腺增生

按产品分类

  • 泌尿科
  • 荷尔蒙疗法
  • 妇科
  • 抗感染药
  • 其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲泌尿生殖药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。泌尿生殖药物市场的主要参与者包括雅培、百时美施贵宝公司、诺华公司、基因泰克公司、F.霍夫曼-拉罗氏有限公司、Ionis Pharmaceuticals Inc.、礼来公司、默克公司、辉瑞公司、阿斯特捷利康、葛兰素史克、梯瓦製药工业有限公司、拜耳公司、艾尔建、Antares Pharma。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：泌尿生殖药物 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按指标进行的市场吸引力分析
    • 按产品分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球泌尿生殖药物市场分析：依适应症分类

  • 按指示概述
  • 按指示进行历史和预测资料分析
  • 摄护腺癌
  • 卵巢癌
  • 膀胱癌
  • 子宫颈癌
  • 肾癌
  • 性功能障碍
  • 泌尿道感染
  • 尿失禁和膀胱过动症
  • 性传染病
  • 间质性膀胱炎
  • 血尿
  • 良性摄护腺增生

第 6 章：全球泌尿生殖药物市场分析：按产品

  • 概述（按产品）
  • 按产品分类的历史和预测资料分析
  • 泌尿科
  • 荷尔蒙疗法
  • 妇科
  • 抗感染药
  • 其他的

第 7 章：全球泌尿生殖药物市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 8 章：泌尿生殖药品公司的竞争格局

  • 泌尿生殖药物市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 9 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Abbott
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bristol-Myers Squibb Co.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Novartis AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Genentech Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • F. Hoffmann-La RocheLtd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Ionis Pharmaceuticals Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Eli Lilly And Company
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Merck & Co. Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • AstraZeneca
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • GlaxoSmithKline
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Teva Pharmaceutical Industries Ltd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bayer AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Allergan
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Antares Pharma
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR112115297

The global demand for Genitourinary Drugs Market is presumed to reach the market size of nearly USD 41.22 Billion by 2032 from USD 35.23 Billion in 2023 with a CAGR of 1.76% under the study period 2024-2032.

Genitourinary drugs are pharmaceutical agents designed to treat disorders & diseases affecting the urinary tract and reproductive organs. These drugs encompass various therapeutic categories, including antibiotics, antivirals, antifungals, hormones, and immunosuppressants. They are used to manage conditions such as urinary tract infections (UTIs), erectile dysfunction, benign prostatic hyperplasia (BPH), infertility, sexually transmitted infections (STIs), and various cancers of the genitourinary system. Based on the disease or disorder being treated, these drugs may target pathogens, modulate hormone levels, reduce inflammation, or inhibit cancer cell growth.

MARKET DYNAMICS

The genitourinary drugs market is driven by the increasing prevalence of genitourinary disorders, advancements in drug development, and evolving healthcare demographics. The rising incidence of genitourinary conditions such as UTIs, prostate disorders, and sexually transmitted diseases propels the demand for effective pharmaceutical treatments. Rapid urbanization, lifestyle changes, and aging populations contribute to a higher disease burden, necessitating continuous innovation in genitourinary drug therapies. Moreover, advancements in drug delivery systems, personalized medicine approaches, and biomarker identification enhance treatment efficacy and patient outcomes. Targeted therapies for conditions like prostate cancer and erectile dysfunction are expanding treatment options and improving the quality of life for affected individuals. Furthermore, growing healthcare expenditure and investments in urological research drive market expansion. Pharmaceutical companies focus on developing novel therapies & expanding indications for existing drugs to address unmet medical needs in genitourinary medicine. Increasing awareness about reproductive health, proactive screening initiatives, and patient education programs also foster genitourinary drugs market growth. Healthcare providers and policymakers prioritize preventive care and early intervention strategies, supporting market uptake of genitourinary drugs. However, stringent regulatory requirements for drug approval and patent expirations challenge market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Genitourinary Drugs. The growth and trends of Genitourinary Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Genitourinary Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

  • Prostate Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Renal Cancer
  • Erectile Dysfunction
  • Urinary Tract Infections
  • Urinary Incontinence & Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Haematuria
  • Benign Prostatic Hyperplasia

By Product

  • Urologicals
  • Hormonal Therapy
  • Gynecological
  • Anti-Infectives
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Genitourinary Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genitourinary Drugs market include Abbott, Bristol-Myers Squibb Co., Novartis AG, Genentech Inc., F. Hoffmann-La RocheLtd., Ionis Pharmaceuticals Inc., Eli Lilly And Company, Merck & Co. Inc., Pfizer Inc., AstraZeneca, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Bayer AG, Allergan, Antares Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. GENITOURINARY DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Indication
    • 3.7.2 Market Attractiveness Analysis By Product
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY INDICATION

  • 5.1. Overview By Indication
  • 5.2. Historical and Forecast Data Analysis By Indication
  • 5.3. Prostate Cancer Historic and Forecast Sales By Regions
  • 5.4. Ovarian Cancer Historic and Forecast Sales By Regions
  • 5.5. Bladder Cancer Historic and Forecast Sales By Regions
  • 5.6. Cervical Cancer Historic and Forecast Sales By Regions
  • 5.7. Renal Cancer Historic and Forecast Sales By Regions
  • 5.8. Erectile Dysfunction Historic and Forecast Sales By Regions
  • 5.9. Urinary Tract Infections Historic and Forecast Sales By Regions
  • 5.10. Urinary Incontinence & Overactive Bladder Historic and Forecast Sales By Regions
  • 5.11. Sexually Transmitted Diseases Historic and Forecast Sales By Regions
  • 5.12. Interstitial Cystitis Historic and Forecast Sales By Regions
  • 5.13. Haematuria Historic and Forecast Sales By Regions
  • 5.14. Benign Prostatic Hyperplasia Historic and Forecast Sales By Regions

6. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY PRODUCT

  • 6.1. Overview By Product
  • 6.2. Historical and Forecast Data Analysis By Product
  • 6.3. Urologicals Historic and Forecast Sales By Regions
  • 6.4. Hormonal Therapy Historic and Forecast Sales By Regions
  • 6.5. Gynecological Historic and Forecast Sales By Regions
  • 6.6. Anti-Infectives Historic and Forecast Sales By Regions
  • 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE GENITOURINARY DRUGS COMPANIES

  • 8.1. Genitourinary Drugs Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF GENITOURINARY DRUGS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Abbott
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Bristol-Myers Squibb Co.
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Novartis AG
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. Genentech Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. F. Hoffmann-La RocheLtd.
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. Ionis Pharmaceuticals Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. Eli Lilly And Company
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. Merck & Co. Inc.
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. Pfizer Inc.
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments
  • 9.12. AstraZeneca
    • 9.12.1 Company Overview
    • 9.12.2 Company Revenue
    • 9.12.3 Products
    • 9.12.4 Recent Developments
  • 9.13. GlaxoSmithKline
    • 9.13.1 Company Overview
    • 9.13.2 Company Revenue
    • 9.13.3 Products
    • 9.13.4 Recent Developments
  • 9.14. Teva Pharmaceutical Industries Ltd.
    • 9.14.1 Company Overview
    • 9.14.2 Company Revenue
    • 9.14.3 Products
    • 9.14.4 Recent Developments
  • 9.15. Bayer AG
    • 9.15.1 Company Overview
    • 9.15.2 Company Revenue
    • 9.15.3 Products
    • 9.15.4 Recent Developments
  • 9.16. Allergan
    • 9.16.1 Company Overview
    • 9.16.2 Company Revenue
    • 9.16.3 Products
    • 9.16.4 Recent Developments
  • 9.17. Antares Pharma
    • 9.17.1 Company Overview
    • 9.17.2 Company Revenue
    • 9.17.3 Products
    • 9.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Indication (USD MN)
  • Prostate Cancer Market Sales By Geography (USD MN)
  • Ovarian Cancer Market Sales By Geography (USD MN)
  • Bladder Cancer Market Sales By Geography (USD MN)
  • Cervical Cancer Market Sales By Geography (USD MN)
  • Renal Cancer Market Sales By Geography (USD MN)
  • Erectile Dysfunction Market Sales By Geography (USD MN)
  • Urinary Tract Infections Market Sales By Geography (USD MN)
  • Urinary Incontinence & Overactive Bladder Market Sales By Geography (USD MN)
  • Sexually Transmitted Diseases Market Sales By Geography (USD MN)
  • Interstitial Cystitis Market Sales By Geography (USD MN)
  • Haematuria Market Sales By Geography (USD MN)
  • Benign Prostatic Hyperplasia Market Sales By Geography (USD MN)
  • Analysis By Product (USD MN)
  • Urologicals Market Sales By Geography (USD MN)
  • Hormonal Therapy Market Sales By Geography (USD MN)
  • Gynecological Market Sales By Geography (USD MN)
  • Anti-Infectives Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Genitourinary Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Genitourinary Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Genitourinary Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Product
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Indication (USD MN)
  • Prostate Cancer Market Sales By Geography (USD MN)
  • Ovarian Cancer Market Sales By Geography (USD MN)
  • Bladder Cancer Market Sales By Geography (USD MN)
  • Cervical Cancer Market Sales By Geography (USD MN)
  • Renal Cancer Market Sales By Geography (USD MN)
  • Erectile Dysfunction Market Sales By Geography (USD MN)
  • Urinary Tract Infections Market Sales By Geography (USD MN)
  • Urinary Incontinence & Overactive Bladder Market Sales By Geography (USD MN)
  • Sexually Transmitted Diseases Market Sales By Geography (USD MN)
  • Interstitial Cystitis Market Sales By Geography (USD MN)
  • Haematuria Market Sales By Geography (USD MN)
  • Benign Prostatic Hyperplasia Market Sales By Geography (USD MN)
  • Global Market Analysis By Product (USD MN)
  • Urologicals Market Sales By Geography (USD MN)
  • Hormonal Therapy Market Sales By Geography (USD MN)
  • Gynecological Market Sales By Geography (USD MN)
  • Anti-Infectives Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.